DILITUS 0.2MG

DILITUS 0.2MG

Availability :

Out Of Stock

Product Code : 107713870700602

Short Description

Dilitus is an α-glucosidase inhibitor used to manage postprandial hyperglycemia in type 2 diabetes mellitus patients, either alone or in combination with other antidiabetic agents.

Name	Brand	Generic Name	Strength	PPF	Price
DILITUS 0.2MG	General Pharmaceuticals Ltd.	VOGLIBOSE	0.2mg	TABLET	6

৳ 6

Select Color

Select Size

Qty :

Description

• রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন

Indications:

Dilitus is indicated for:

Non-insulin-dependent diabetes mellitus (NIDDM) patients as monotherapy.
In combination with other oral hypoglycemic agents.
In addition to insulin in diabetes mellitus patients.
Prevention of onset of type 2 diabetes mellitus in impaired glucose tolerance.
In elderly patients and those with hepatic dysfunction or mild to moderate renal impairments in whom other oral hypoglycemic agents are contraindicated or need to be used with caution.
In glycogen storage disease, it is helpful in preventing hypoglycemia in patients with type I glycogen storage disease.
In non-diabetic hyperinsulinemia, it is helpful in preventing hypoglycemic attacks.

Pharmacology:

Voglibose is an α-glucosidase inhibitor that delays the digestion and absorption of carbohydrates by inhibiting the enzymes responsible for breaking down complex carbohydrates into glucose. This results in a reduction in postprandial blood glucose levels.

Dosage:

Adults: 0.2 mg orally three times a day before meals. If the effect is insufficient, the dose may be increased to 0.3 mg.
Elderly: Initiate at a lower dose (e.g., 0.1 mg) and adjust as necessary.
Renal Impairment: No dose adjustment is required due to negligible renal excretion.

Administration:

Take the tablet orally with water just before meals.
Adhere to the prescribed dosage and schedule as directed by the healthcare provider.

Interaction:

Enhancing Hypoglycemic Effect: β-blockers, salicylic acid preparations, monoamine oxidase inhibitors, fibrate derivatives, warfarin.
Diminishing Hypoglycemic Effect: Adrenaline, adrenocortical hormones, thyroid hormones.

Contraindications:

Hypersensitivity to Voglibose or any component of the formulation.
Diabetic ketoacidosis, diabetic pre-coma.
Severe infection, before and after surgery or serious trauma.
Gastrointestinal obstruction or predisposition to it.

Side Effects:

Common: Flatulence, abdominal distension, diarrhea, abdominal pain, constipation, loss of appetite, nausea, vomiting, heartburn, increased gas, and symptoms resembling intestinal obstruction due to increased intestinal gas.
Rare: Hepatotoxicity, serious liver dysfunction with increased liver enzymes, jaundice, anemia, numbness, edema, blurred vision, hot flushes, malaise, weakness, hyperkalemia, increased pancreatic enzymes (serum amylase).

Pregnancy & Lactation:

Pregnancy: Safety during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.
Lactation: It is not known whether Voglibose is excreted in human milk. Exercise caution when administered to a nursing mother.